Company / Net Debt per Share
Jazz Pharmaceuticals Net Debt per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
$65.42
FY2025
5-year range
$59.37 / $97.18
FY2021-FY2025
Trend
+10.2%
vs FY2024
Sector context
#2 of 82
Health Care
What the data says
Among 82 Health Care companies, Jazz Pharmaceuticals is in the bottom 2% for net debt per share. Net Debt per Share returned to growth in FY2025 after 3 years of decline, reaching $65.42.
Based on SEC 10-K filings.
65.42 in FY2025 with a 5-year CAGR of +28.8%. Ranks 2nd among 82 companies in Health Care.
Remained stable around $65.42 over the past 2 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -5.9%
- 5-Year CAGR
- +28.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 82This company $65.42 Sector average $1.13
▼
+5688.1% above sector average
Key checks
Key Insights
- In FY2025, net debt per share increased 10.2% year-over-year.
- Ranks #2 out of 82 companies in the Health Care sector.
- Peak net debt per share was recorded in FY2021.
- Lowest net debt per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $65.42 | +10.2% |
| FY2024 | $59.37 | -10.8% |
| FY2023 | $66.55 | -15.3% |
| FY2022 | $78.58 | -19.1% |
| FY2021 | $97.18 | +426.0% |
| FY2020 | $18.47 | +9.9% |
| FY2019 | $16.81 | -23.1% |
| FY2018 | $21.85 | +9.4% |
| FY2017 | $19.98 | -9.0% |
| FY2016 | $21.95 | +566.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026